Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials Journal Article
| Authors: | Soumerai, J. D.; Ni, A.; Xing, G.; Huang, J.; Furman, R. R.; Jones, J.; Sharman, J. P.; Hallek, M.; Adewoye, A. H.; Dubowy, R.; Dreiling, L.; Zelenetz, A. D. |
| Article Title: | Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials |
| Abstract: | The CLL-IPI is a risk-weighted prognostic model for previously untreated patients with chronic lymphocytic leukemia (CLL), but has not been evaluated in patients with relapsed CLL or on novel therapies. We evaluated the CLL-IPI in 897 patients with relapsed/refractory CLL in 3 randomized trials testing idelalisib (PI3Kδ inhibitor). The CLL-IPI identified patients as low (2.2%), intermediate (12.8%), high (48.7%), and very high (36.2%) risk and was prognostic for survival (log-rank p <.0001; C-statistic 0.706). Of CLL-IPI factors, age >65, β2-microglobulin >3.5mg/L, unmutated immunoglobulin heavy chain variable region gene, and deletion 17p/TP53 mutation were independently prognostic, but Rai I-IV or Binet B/C was not. The CLL-IPI is prognostic for survival in relapsed CLL and with idelalisib therapy. However, low/intermediate risk is uncommon, and regression parameters of individual factors in this risk-weighted model appear different in relapsed CLL. Reassessment of the weighting of the individual variables might optimize the model in this setting. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | leukemia; lymphoma; chronic lymphocytic leukemia; prognostication; idelalisib; cll-ipi |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 60 |
| Issue: | 6 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2019-01-01 |
| Start Page: | 1438 |
| End Page: | 1446 |
| Language: | English |
| DOI: | 10.1080/10428194.2018.1540782 |
| PUBMED: | 30407886 |
| PROVIDER: | scopus |
| PMCID: | PMC6545166 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 March 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work